Biochemistry (Moscow)

, Volume 81, Issue 5, pp 439–444 | Cite as

Effect of fibrinogen on platelet reactivity measured by the VerifyNow P2Y12 assay

  • A. B. DobrovolskyEmail author
  • P. S. Laguta
  • E. V. Guskova
  • E. B. Yarovaya
  • E. V. Titaeva
  • A. N. Storozhilova
  • E. P. Panchenko
Accelerated Publication


The VerifyNow assay is based upon the ability of activated platelets to cross-link beads coated with fibrinogen. However, fibrinogen is an abundant protein of blood, and therefore it may affect test results by competing with fibrinogen of beads for binding to platelets. To test this assumption, we assessed the influence of artificial alteration of fibrinogen level in blood samples obtained from donors (n = 9) and patients on clopidogrel therapy (n = 8) on the results of the VerifyNow P2Y12 assay. Fibrinogen level was altered by adding to blood samples 1/10 volume of fibrinogen solution (10.56 g/liter) or corresponding buffer. Relative to baseline, addition of buffer significantly increased platelet reactivity, whereas addition of fibrinogen decreased it. Analysis of the relationship between change in platelet reactivity values (dBase and dPRU) and change in fibrinogen concentration (dFg) revealed strong negative correlations: dBase =–63.3 × dFg–27.1 (r =–0.924, p < 0.0005) and dPRU =–54.4 × dFg–21.8 (r =–0.764, p < 0.0005). Thus, the results of our experiments suggest that: (i) blood fibrinogen strongly influences results of the VerifyNow P2Y12 assay, and (ii) correcting for fibrinogen effect may be needed to improve the accuracy of the test in the measuring of antiplatelet effect of clopidogrel therapy.


platelets fibrinogen P2Y12 inhibitors VerifyNow test 



arbitrary units of platelet aggregation


platelet reactivity mediated by PAR-1 and -4


cardiovas-cular diseases




glycoprotein complex binding Fg

PAR-1 and -4

receptors activated by proteases


platelet reactivity units mediated by P2Y12


platelet ADP receptor


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sanz, J., Moreno, P. R., and Fuster, V. (2013) The year in atherothrombosis, J. Am. Coll. Cardiol., 62, 1131–1143.CrossRefPubMedGoogle Scholar
  2. 2.
    Cattaneo, M. (2012) Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J. Thromb. Haemost., 10, 327–336.CrossRefPubMedGoogle Scholar
  3. 3.
    Aradi, D., Kirtane, A., Bonello, L., Gurbel, P. A., Tantry, U. S., Huber, K., Freynhofer, M. K., Ten Berg, J., Janssen, P., Angiolillo, D. J., Siller-Matula, J. M., Marcucci, R., Patti, G., Mangiacapra, F., Valgimigli, M., Morel, O., Palmerini, T., Price, M. J., Cuisset, T., Kastrati, A., Stone, G. W., and Sibbing, D. (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention, Eur. Heart J., 36, 1762–1771.CrossRefPubMedGoogle Scholar
  4. 4.
    Malinin, A., Pokov, A., Spergling, M., Defranco, A., Schwartz, K., Schwartz, D., Mahmud, E., Atar, D., and Serebruany, V. (2007) Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study, Thromb. Res., 119, 277–284.CrossRefPubMedGoogle Scholar
  5. 5.
    Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis, JAMA, 294, 1799–1809.Google Scholar
  6. 6.
    Titaeva, E. V., Dobrovolsky, A. B., and Titov, V. N. (1988) A simple method for isolation of highly purified preparations of fibrinogen from human plasma, Lab. Delo, 1, 29–32.PubMedGoogle Scholar
  7. 7.
    Dobrovolsky, A. B., Titaeva, E. V., Yarovaya, E. B., Storozhilova, A. N., Zhernakova, Yu. V., Oschepkova, E. V., Panchenko, E. P., Trubacheva, I. A., Serebryakova, V. N., Kaveshnikov, V. S., Chazova, I. E., and Karpov, R. S. (2013) Coagulation risk factors of heart disease in the adult population of Tomsk, System Hypertension, 10, 50–54.Google Scholar
  8. 8.
    Bennett, J. S. (2015) Regulation of integrins in platelets, Biopolymers, 104, 323–333.CrossRefPubMedGoogle Scholar
  9. 9.
    Yakushkin, V. V., Zyuryaev, I. T., Khaspekova, S. G., Sirotkina, O. V., Ruda, M. Y., and Mazurov, A. V. (2011) Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome, Platelets, 22, 243–251.CrossRefPubMedGoogle Scholar
  10. 10.
    Price, M. J., Angiolillo, D. J., Teirstein, P. S., Lillie, E., Manoukian, S. V., Berger, P. B., Tanguay, J. F., Cannon, C. P., and Topol, E. J. (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial, Circulation, 124, 1132–1137.CrossRefPubMedGoogle Scholar
  11. 11.
    Montalescot, G., Range, G., Silvain, J., Bonnet, J. L., Boueri, Z., Barthelemy, O., Cayla, G., Belle, L., Van Belle, E., Cuisset, T., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrie, D., Rousseau, H., Aubry, P., Monsegu, J., Sabouret, P., O’Connor, S. A., Abtan, J., Kerneis, M., Saint-Etienne, C., Beygui, F., Vicaut, E., and Collet, J. P. (2014) High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study, Circulation, 129, 2136–2243.CrossRefPubMedGoogle Scholar
  12. 12.
    Stone, G. W., Witzenbichler, B., Weisz, G., Rinaldi, M. J., Neumann, F. J., Metzger, D. C., Henry, T. D., Cox, D. A., Duffy, P. L., Mazzaferri, E., Gurbel, P. A., Xu, K., Parise, H., Kirtane, A. J., Brodie, B. R., Mehran, R., and Stuckey, T. D. (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study, Lancet, 382, 614–623.CrossRefPubMedGoogle Scholar
  13. 13.
    Siller-Matula, J. M., Trenk, D., Schror, K., Gawaz, M., Kristensen, S. D., Storey, R. F., and Huber, K. (2015) How to improve the concept of individualized antiplatelet therapy with P2Y12 receptor inhibitors–is an algorithm the answer? Thromb. Haemost., 113, 37–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Legrand, D., Barbato, E., Chenu, P., Magne, J., Vrolix, M., Wijns, W., and Legrand, V. (2015) The STIB score: a simple clinical test to predict clopidogrel resistance, Acta Cardiol., 70, 516–521.PubMedGoogle Scholar
  15. 15.
    Kakouros, N., Kickler, T. S., Laws, K. M., and Rade, J. J. (2013) Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness, J. Thromb. Haemost., 11, 1814–1822.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim, Y. G., Suh, J.-W., Park, J. J., Oh, I.-Y., Yoon, C.-H., Cho, Y. S., Youn, T. J., Chae, I. H., and Choi, D. J. (2014) Different influences of hematocrit on the results of two point-of-care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry, PLoS One, 9, e114053.PubMedGoogle Scholar
  17. 17.
    Pendyala, L. K., Loh, J. P., Lhermusier, T., Minha, S., Magalhaes, M., Torguson, R., Chen, F., Satler, L. F., Pichard, A. D., and Waksman, R. (2014) Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel? Am. Heart J., 168, 545–551.CrossRefPubMedGoogle Scholar
  18. 18.
    Mahmud, E., Cavendish, J. J., Tsimikas, S., Ang, L., Nguyen, C., Bromberg-Marin, G., Schnyder, G., Keramati, S., Palakodeti, V., Penny, W. F., and DeMaria, A. N. (2007) Elevated plasma fibrinogen level predicts suboptimal response to therapy with both singleand doublebolus eptifibatide during percutaneous coronary intervention, J. Am. Coll. Cardiol., 49, 2164–2171.CrossRefGoogle Scholar
  19. 19.
    Ang, L., Palakodeti, V., Khalid, A., Tsimikas, S., Idrees, Z., Tran, P., Clopton, P., Zafar, N., Bromberg-Marin, G., Keramati, S., and Mahmud, E. (2008) Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel, J. Am. Coll. Cardiol., 52, 1052–1059.CrossRefPubMedGoogle Scholar
  20. 20.
    Ang, L., Bin Thani, K., Ilapakurti, M., Lee, M. S., Palakodeti, V., and Mahmud, E. (2013) Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention, J. Am. Coll. Cardiol., 61, 23–34.CrossRefPubMedGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2016

Authors and Affiliations

  • A. B. Dobrovolsky
    • 1
    Email author
  • P. S. Laguta
    • 1
  • E. V. Guskova
    • 1
  • E. B. Yarovaya
    • 2
  • E. V. Titaeva
    • 1
  • A. N. Storozhilova
    • 1
  • E. P. Panchenko
    • 1
  1. 1.Russian Cardiology Research and Production ComplexMinistry of HealthcareMoscowRussia
  2. 2.Lomonosov Moscow State UniversityFaculty of Mechanics and MathematicsMoscowRussia

Personalised recommendations